EndeavorRx is a prescription-only digital therapeutic (Software as a Medical Device - SaMD) indicated to improve attention function as measured by computer-based testing in children ages 8-17 years old with primarily inattentive or combined-type Attention-Deficit/Hyperactivity Disorder (ADHD), who have a demonstrated attention issue. It is the first FDA-authorized treatment delivered through a video game.
The treatment is delivered through an action-packed, mission-based racing game experience. It utilizes Akili's patented Selective Stimulus Management Engine (SSME™) technology, which employs adaptive algorithms to deliver specific sensory stimuli and simultaneous motor challenges. This technology is designed to directly target and activate the neural systems that play a key role in attentional control.
Key Features and Use:
- Targeted Treatment: Designed to specifically target the inattention component of ADHD.
- Personalized & Adaptive: The SSME algorithm adjusts difficulty and speed in real-time based on the player's performance to maintain a therapeutic challenge.
- Regimen: Recommended use is approximately 25 minutes per day, 5 days per week, for at least 4 consecutive weeks, or as recommended by a healthcare provider.
- Multimodal Therapy: EndeavorRx is intended for use as part of a broader therapeutic program that may include clinician-directed therapy, medication, and/or educational programs; it is not a stand-alone therapeutic or a substitute for medication.
- Caregiver Companion App: The EndeavorRx Insight® companion app allows caregivers to monitor the child's in-game mission completion and effort score.
Target Users: Children ages 8-17 with primarily inattentive or combined-type ADHD, as prescribed by a licensed healthcare provider.